VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from th
VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from the European Institute of Oncology in Milan. After his talk at the St Gallen breast cancer conference he discussed criteria for individualizing optimal endocrine adjuvant treatments with Oncology Times reporter Sarah Maxwell.